In HELIOS-B (n=654), baseline tafamidis use (40%) did not significantly modify vutrisiran’s effect on mortality plus ...

Seshadri, who moderated a discussion at the August 11 Institute for Value-Based Medicine ® event in San Francisco, said travel distance to a CAR T-cell center is a major barrier, compounded by ...

Kalshi, a prediction betting market app, announced new contracts in July 2026 for FDA approvals on various cancer and ...

REMS certification requirements, split hospital/community EMRs, and limited trained infusion staffing create friction points ...

Andrew Kuykendall, MD, lead investigator for the VERIFY trial supporting the approval, said rusfertide is used to treat erythrocytosis in polycythemia vera.

Hospital resources, not clinical preference, often decide which MG rescue therapy a patient receives, Richard Nowak, MD, MS, ...

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press. In its article, Becker's ...